Philip Castle Rejoins DCEG as a Senior Investigator

March 18, 2021, by DCEG Staff

In March 2021, Philip E. Castle, Ph.D., M.P.H., was reinstated with scientific tenure by the NIH and rejoined DCEG as a senior investigator in the Clinical Genetics Branch. He holds a dual appointment as Director of the NCI Division of Cancer Prevention, to which he was appointed in July 2020.

Dr. Castle is an internationally recognized expert in the field of cervical cancer prevention. He has led and contributed critical insights to the design and conduct of randomized trials and cohort studies of the effectiveness of human papillomavirus (HPV) vaccinations, screening regimens, and the natural history of cervical precancer and cancer. Another focus of his research portfolio is the development and validation of new technologies for cervical cancer prevention, including HPV tests, many of which have been approved for clinical use by the U.S. Food and Drug Administration (FDA). His work has enhanced clinical practice and informed the U.S. screening and management guidelines, notably the implementation of primary HPV testing for cervical cancer screening. 

Dr. Castle has a long history with DCEG, first joining the Division in 2000 as a Cancer Prevention Fellow under the mentorship of Dr. Mark Schiffman. He became a tenure-track investigator in 2003 and a tenured senior investigator in 2010. In 2011, he became Executive Director and later Chief Scientific Officer of ASCCP (formerly the American Society for Colposcopy and Clinical Pathology). Most recently, Dr. Castle was a tenured professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine, and the Executive Director and Co-Founder of the Global Coalition Against Cervical Cancer.